TGFB1 C-509T多态性与早期乳腺癌放疗后纤维化的关联
这项前瞻性队列研究嵌套于一项随机临床试验,纳入287例接受保乳术后全乳照射的0-IIA期乳腺癌女性,分析TGFB1 C-509T变异与3年乳腺纤维化的关联。多变量分析显示C-509T和术后美容效果是纤维化的独立风险因素。
要点
- 多变量分析中C-509T(OR 4.47,95%CI 1.25-15.99)与纤维化风险独立相关。
- 检测TGFB1基因型可能有助于乳腺癌局部治疗的个体化决策。
核心结论
- TGFB1 C-509T等位基因是乳腺癌放疗后纤维化风险的关键决定因素。
- 该研究似乎是首个对放疗纤维化基因组标志物的前瞻性验证。
研究设计与样本
- 前瞻性队列研究,嵌套于一项开放标签随机临床试验(NCT01266642)。
- 比较低分次全乳照射(42.56 Gy/16次)与常规分次全乳照射(50 Gy/25次)。
- 纳入287例40岁及以上、病理确诊0-IIA期乳腺癌、接受保乳手术的女性,2011年2月至2014年2月入组,随访至少3年。
- 最终174例有TGFB1基因型和3年放疗毒性数据可供分析。
主要发现
- 174例可分析患者中,89例(51%)携带至少1个C-509T拷贝,平均(SD)年龄60(8)岁。
- C-509T携带者中12/87例(13.8%)发生≥2级乳腺纤维化,无变异者中3/80例(3.8%)。
关键数值与推荐
- 主要结局为放疗后3年≥2级乳腺纤维化,采用LENT/SOMA量表(范围0-3)评估。
- 暴露因素为TGFB1基因相对于第一主要转录起始点-509位的C-to-T单核苷酸多态性(C-509T)。
- 统计方法采用单侧Fisher精确检验和多变量逻辑回归。
临床怎么用
- 评估TGFB1基因型可能有助于识别放疗后纤维化高风险患者。
- 结合术后美容效果和基因型信息,或可促进乳腺癌局部区域治疗的个体化决策。
局限性
- 287例入组患者中仅174例有基因型和3年毒性数据,存在数据缺失。
- 研究嵌套于特定随机试验人群(0-IIA期、保乳术后),外推性需谨慎。
- 原文未报告其他局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Whether genetic factors can identify patients at risk for radiation-induced fibrosis remains unconfirmed. OBJECTIVE: To assess the association between the C-509T variant allele in the promoter region of TGFB1 and breast fibrosis 3 years after radiotherapy. DESIGN, SETTING, AND PARTICIPANTS: This is an a priori-specified, prospective, cohort study nested in an open-label, randomized clinical trial, which was conducted in community-based and academic cancer centers to compare hypofractionated whole-breast irradiation (WBI) (42.56 Gy in 16 fractions) with conventionally fractionated WBI (50 Gy in 25 fractions) after breast-conserving surgery. In total, 287 women 40 years or older with pathologically confirmed stage 0 to IIA breast cancer treated with breast-conserving surgery were enrolled from February 2011 to February 2014. Patients were observed for a minimum of 3 years. Outcomes were compared using the 1-sided Fisher exact test and multivariable logistic regression. EXPOSURES: A C-to-T single-nucleotide polymorphism at position -509 relative to the first major transcription start site (C-509T) of the TGFB1 gene. MAIN OUTCOMES AND MEASURES: The primary outcome was grade 2 or higher breast fibrosis as assessed using the Late Effects Normal Tissue/Subjective, Objective, Medical Management, Analytic scale (range, 0 to 3) three years after radiotherapy. RESULTS: Among 287 women enrolled in the trial, TGFB1 genotype and 3-year radiotherapy-induced toxicity data were available for 174 patients, of whom 89 patients (51%) with a mean (SD) age of 60 (8) years had at least 1 copy of C-509T. Grade 2 or higher breast fibrosis was present in 12 of 87 patients with C-509T (13.8%) compared with 3 of 80 patients without the allele variant (3.8%) (absolute difference, 10.0%; 95% CI, 1.7%-18.4%; P = .02). The results of multivariable analyses indicated that only C-509T (odds ratio, 4.47; 95% CI, 1.25-15.99; P = .02) and postoperative cosmetic outcome (odds ratio, 7.09; 95% CI, 2.41-20.90; P < .001) were significantly associated with breast fibrosis risk. CONCLUSIONS AND RELEVANCE: To date, this study seems to be the first prospective validation of a genomic marker for radiation fibrosis. The C-509T allele in TGFB1 is a key determinant of breast fibrosis risk. Assessing TGFB1 genotype may facilitate a more personalized approach to locoregional treatment decisions in breast cancer. TRIAL REGISTRATION: ClinicalTrials.gov identifier: NCT01266642.
引用
- Grossberg AJ, Lei X, Xu T, et al. Association of Transforming Growth Factor β Polymorphism C-509T With Radiation-Induced Fibrosis Among Patients With Early-Stage Breast Cancer: A Secondary Analysis of a Randomized Clinical Trial. JAMA Oncol. 2018. PMID: 30027292. doi:10.1001/jamaoncol.2018.2583
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。